Cost-effectiveness analysis of cetuximab as third-line treatment in metastatic colorectal cancer

被引：0
|
作者：
Romeo, M. [1 ]
Soler, G. [1 ]
Martinez Villacampa, M. [1 ]
Laquente, B. [1 ]
Lopez Doriga, A. [1 ]
Pisa, A. [1 ]
Rey, M. [1 ]
Santos, C. [1 ]
Salazar, R. [1 ]
Germa Lluch, J. R. [1 ]
机构：
[1] Inst Catala Oncol, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.15090
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15090
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
    Zhi Peng
    Xingduo Hou
    Yangmu Huang
    Tong Xie
    Xinyang Hua
    BMC Cancer, 20
  • [2] Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
    Peng, Zhi
    Hou, Xingduo
    Huang, Yangmu
    Xie, Tong
    Hua, Xinyang
    BMC CANCER, 2020, 20 (01)
  • [3] Cost-effectiveness analysis of fruquintinib as third-line treatment for patients with metastatic colorectal cancer
    Zhang, Peng-Fei
    Xie, Dan
    Li, Qiu
    TUMORI JOURNAL, 2020, 106 (05): : 400 - 405
  • [4] Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer
    Zhong, Jiayun
    Liu, Yu
    Fu, Qian
    Huang, Dan
    Gong, Wenjun
    Zou, Jian
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 593 - 602
  • [5] COST-EFFECTIVENESS OF CETUXIMAB VERSUS PANITUMUMAB IN THIRD-LINE THERAPY FOR CHEMOTHERAPY-REFRACTORY METASTATIC COLORECTAL CANCER IN BRAZIL
    Sasse, Andre
    Carvalho, Adriana
    ANNALS OF ONCOLOGY, 2012, 23 : 100 - 100
  • [6] Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
    Groot, Carin A. Uyl-de
    van Rooijen, Elisabeth M.
    Punt, Cornelis J. A.
    Pescott, Chris P.
    HEALTH ECONOMICS REVIEW, 2018, 8
  • [7] Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
    Carin A. Uyl-de Groot
    Elisabeth M. van Rooijen
    Cornelis J. A. Punt
    Chris P. Pescott
    Health Economics Review, 8
  • [8] Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China
    Guan, Xin
    Li, Hongchao
    Xiong, Xiaomo
    Peng, Cike
    Wang, Ning
    Ma, Xiao
    Ma, Aixia
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 339 - 344
  • [9] THE COST EFFECTIVENESS OF CETUXIMAB (ERBITUX) IN THE THIRD LINE TREATMENT OF METASTATIC COLORECTAL CANCER IN THE UK
    Perard, R.
    Samyshkin, Y.
    Guillermin, A. L. G.
    VALUE IN HEALTH, 2011, 14 (07) : A450 - A450
  • [10] COST-EFFECTIVENESS ANA LYSIS OF REGORAFENIB FOR THIRD-LINE METASTATIC COLORECTAL CANCER (MCRC) COMPARED TO CETUXIMAB PLUS IRINOTECAN IN CHINA
    Liu, J.
    Zhu, S.
    Sun, W.
    Tao, L.
    Xiao, D.
    Xuan, J.
    VALUE IN HEALTH, 2018, 21 : S33 - S33
12345